Cullinan Therapeutics, Inc.

Ownership Transactions Reported by 24 Insiders

Symbol
CGEM on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
One Main Street, Suite 1350, Cambridge, MA

Insiders trading volume in the past year

Cullinan Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Ansbert Gadicke Director $103M Jun 22, 2022
UBS Oncology Impact Fund L.P. 10%+ Owner $95.3M Sep 16, 2021
Morana Jovan-Embiricos 10%+ Owner $56.4M Jun 24, 2022
F2 Vision SCS 10%+ Owner $55.8M Aug 2, 2022
F2 Bioscience I 2017 Ltd 10%+ Owner $55.2M Jun 21, 2022
Patrick Baeuerle Chief Scientific Officer $5.2M Feb 17, 2023
Nadim Ahmed President and CEO, Director $4.39M -$39.5K -0.89% Feb 22, 2024
Corrine Savill Chief Business Officer $3.29M -$1.7M -34.1% Feb 22, 2024
Thomas Ebeling Director $2.43M Jun 10, 2024
Jeffrey Trigilio Chief Financial Officer $2.17M -$34.6K -1.57% Feb 22, 2024
Jennifer Michaelson Chief Scientific Officer $2.1M -$2.09M -49.9% Sep 5, 2024
Jeffrey Alan Jones Chief Medical Officer $1.92M -$19K -0.98% Feb 22, 2024
Jacquelyn Sumer Chief Legal Officer $1.52M -$14.3K -0.93% Feb 22, 2024
Leigh Zawel Chief Scientific Officer, Small Molecules $870K Feb 11, 2022
Bvf Partners L P/Il 10%+ Owner $799K Jan 19, 2023
Raymond T. Keane Chief Legal Officer $301K Feb 11, 2022
Nate Nguyen Interim PAO and PFO $216K Mar 29, 2024
Mary Kay Fenton Chief Financial Officer Apr 29, 2024
David D. Meek Director May 15, 2024
Mary Thistle Director Aug 8, 2024
Anne-Marie Martin Director Jun 26, 2024
David P. Ryan Director Jun 26, 2024
Anthony Rosenberg Director Jun 26, 2024
Stephen W. Webster Director Jun 26, 2024

Recent Insider Transactions by Companies or Individuals for Cullinan Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.